جست‌وجوی استاد و پژوهشگر

• Artificial Intelligence Policy
• Biodefense
• National Security Policy
• +۳ مورد دیگر

Carol R Kuntz serves as an Adjunct Professor in the Science, Technology and International Affairs (STIA) program at Georgetown University, teaching courses on artificial intelligence policy implications. She concurrently holds an adjunct fellowship at the Center for Strategic and International Studies (CSIS) in the Strategic Technologies Program. With over 30 years of U.S. Department of Defense experience, she specializes in adapting national security frameworks to technological disruptions. Her academic credentials include: Ph.D. in Political Science from the Massachusetts Institute of Technology MPA from Princeton University B.A. with Honors from Cornell University Dr. Kuntz's research bridges defense strategy and emerging technologies, focusing on AI governance in military contexts and biotechnological threats. Her work analyzes autonomous weapons ethics, genome editing risks, and WMD defense systems through interdisciplinary lenses spanning computer science, political theory, and public health policy. Recent publications examine AI integration in warfare and genome manipulation governance, revealing consistent themes of proactive policy design for technological existential risks. These studies highlight her strategic approach to anticipating security vulnerabilities before crises emerge. Her accolades include: Secretary of Defense Medal for Meritorious Civilian Service (awarded twice) Dr. Kuntz's government leadership encompassed directing Project Bioshield and the Domestic Nuclear Detection Office, demonstrating extensive grant management and interagency coordination expertise. Her academic mentorship leverages decades of high-stakes policy implementation experience. At CSIS, she contributes to strategic technology assessments while maintaining active academic roles. Her career trajectory—from Cold War defense planning to AI policy—exemplifies continuous adaptation to evolving security paradigms through institutional collaboration.

Crystal R. Watsonمشاهده پروفایل

دانشیار

• Public Health Preparedness
• Biodefense
• Risk Assessment
• +۳ مورد دیگر

Crystal R. Watson is an Associate Professor in the Department of Environmental Health and Engineering at Johns Hopkins University, with a joint role as Senior Associate at the Johns Hopkins Center for Health Security. She specializes in public health preparedness, risk assessment during emergencies, and biodefense policy. She holds a DrPH and MPH from the Johns Hopkins Bloomberg School of Public Health and a BA from the University of Colorado. Her research focuses on federal funding and management of biodefense programs, crisis decision-making, and global health security. Notable projects include assessments of Taiwan’s IHR compliance and analysis of Hurricane Katrina’s medical response. She serves as Associate Editor of Health Security and has authored over 30 peer-reviewed articles. Key contributions include publications on biological threat characterization, pandemic event management, and Ebola risk perception. She advises on policies to address catastrophic biological risks and has led projects funded by federal agencies.

Jennifer Goldenمشاهده پروفایل

دانشیار

• Synthetic Medicinal Chemistry
• Antiviral Drug Development
• Antiparasitic Drug Discovery
• +۳ مورد دیگر

Jennifer Golden is an Associate Professor in the Department of Pharmaceutical Sciences at the School of Pharmacy , University of Wisconsin-Madison . Her research focuses on synthetic medicinal chemistry to develop novel antiviral and anti-parasitic agents for diseases like alphavirus infections and kinetoplastid parasites. The Golden Lab emphasizes chemical methodology development and structure-activity relationship analysis through collaborations assessing compound efficacy in cell and animal models . Research Projects Quinazolinone Rearrangement: Developing synthetic transformations for amidine formation and ring-fused scaffolds. Anti-Alphaviral Agents: Creating FDA-approved therapeutic candidates for mosquito-borne RNA viruses. Broad-Spectrum Antiparasitics: Optimizing compounds for malaria, African sleeping sickness, and leishmaniasis. Publications highlight her work on ML336 (anti-VEEV), quinazolinone derivatives , and collaborations with experts in high-throughput screening and structural biology . Her lab trains students in hit-to-lead optimization , regioselective synthesis , and medicinal chemistry tactics . Education: B.S. (1996) – Eastern Illinois University Ph.D. (2002) – University of Kansas Postdoctoral Research (2004) – Stanford University

Paul Keimمشاهده پروفایل

استاد

• Pathogen Genomics
• Molecular Epidemiology
• Bacterial Pathogens
• +۶ مورد دیگر

Paul Keim is a Distinguished Professor at Northern Arizona University and holds the Cowden Endowed Chair in Microbiology. He serves as a Regents Professor of Biology and leads the Pathogen Genomics Program, a joint initiative between TGen and Northern Arizona University. His work focuses on bacterial pathogen genomics, biodefense, and molecular epidemiology. Institution: Northern Arizona University & TGen Division: Immunology and Microbial Genomics Division Email: pkeim@tgen.org Dr. Keim specializes in genomic forensic analysis of biothreat agents like Bacillus anthracis (anthrax), Yersinia pestis (plague), and Francisella tularensis (tularemia). His research includes understanding pathogen evolution, ecology, and epidemiology to develop advanced diagnostics and therapeutics. He has collaborated with federal agencies on bioterrorism response, notably providing critical forensic analysis during the 2001 anthrax attacks. Key publication trends include genomic surveillance of bacterial pathogens, evolutionary dynamics , and molecular identification tools . His studies often employ whole-genome sequencing , SNP analysis , and MLVA techniques. Scientific Awards Cowden Endowed Chair in Microbiology, Northern Arizona University Dr. Keim's work has shaped modern bioforensic methodologies , particularly for anthrax and plague. His lab's 1993 analysis of the Tokyo anthrax attack linked it to Aum Shinrikyo, establishing genomic tools as critical for biocrime investigations.

• Infectious Diseases
• HIV/AIDS Research
• Antimicrobial Resistance
• +۵ مورد دیگر

Dr. Steven Aronin is an Associate Clinical Professor of Medicine at Yale School of Medicine and serves as Chief of Infectious Disease at Waterbury Hospital. He holds multiple leadership roles including Medical Director of the Waterbury Hospital Infectious Disease and Travel Clinic, Program Director for Ryan White HIV Programs, and Hospital Epidemiologist. His academic work focuses on infectious diseases, particularly meningitis, endocarditis, HIV/AIDS, and antibiotic efficacy. Dr. Aronin completed his MD at Ross University School of Medicine and residency at Yale Primary Care Internal Medicine Program. He has been a Core Faculty member at Waterbury Hospital since 2009 and oversees the Yale-Waterbury Internal Medicine Residency Program's Infectious Disease training. He is also President of the Connecticut Infectious Disease Society. His research emphasizes translational antibiotic studies, particularly sulopenem's efficacy against resistant pathogens like E. coli and K. pneumoniae. Recent work includes phase 3 trials comparing sulopenem to ertapenem for intra-abdominal infections, and evaluating its use in UTIs and anthrax models. Key findings include sulopenem's superior efficacy in UTIs and its potential as a biodefense agent against inhalational anthrax. Dr. Aronin actively contributes to clinical guidelines through studies on HIV screening integration and bacteriuria's clinical impact. His work bridges academic research with direct patient care, emphasizing antibiotic stewardship and improving infectious disease treatment outcomes.

Eileen M. Barryمشاهده پروفایل

استاد

• Vaccine Development
• Enteric Pathogens
• Shigella
• +۵ مورد دیگر

Eileen M. Barry serves as Professor in the Department of Medicine at the University of Maryland School of Medicine, with secondary appointments in Medical and Research Technology and Microbiology and Immunology. She directs education for the Center of Vaccine Development & Global Health, leading research on vaccines against enteric pathogens and biodefense threats. Her academic background includes: B.A. in Biology from University of Delaware (1985) Ph.D. in Microbiology and Immunology from Virginia Commonwealth University Medical College of Virginia (1991) Postdoctoral Fellowship at University of Maryland School of Medicine Center for Vaccine Development (1992-1994) Postdoctoral Fellowship at University of Maryland School of Medicine Center for Vaccine Development (1994-1996) Dr. Barry's research focuses on oral live attenuated vaccines targeting Shigella , enterotoxigenic E. coli (ETEC), and Francisella tularensis . Her work spans pathogen engineering, host-pathogen interactions, and clinical translation, with emphasis on pediatric and military applications. Key methodologies include human enteroid models, BSL3/ABSL3 pathogenesis studies, and immunogenicity assessment. Recent publications reveal a strategic shift toward multivalent platforms and advanced organoid systems for predicting human immune responses. Her scientific recognition includes: University System of Maryland PROMISE Alliance Outstanding Faculty Mentor (2015) Faculty Teacher of the Year Award (2011) Teaching Commendation in Host Defenses (2009/2012) As a dedicated mentor, Dr. Barry has served on Graduate Student Admissions Committees since 2007 and received special recognition for advancing underrepresented STEM students. Her substantial NIH funding portfolio includes: P01AI125181: Pathogenesis of E. Coli and Shigella in Human Enteroid Models (2016-2021) R01AI125841: Serological Assays for Shigella Vaccine Efficacy (2016-2021) R01AI123129: Tularemia Vaccine Protection Correlates (2016-2021) Her laboratory operates BSL2/3 and ABSL2/3 facilities, integrating genetic engineering, organoid models, and genomics to dissect enteric pathogenesis and accelerate vaccine development for global health impact.

Chad J. Royمشاهده پروفایل

استاد

• Aerobiology
• Infectious Disease Research
• Vaccine Development
• +۶ مورد دیگر

Chad J. Roy, PhD, is a Professor of Microbiology and Immunology and Associate Dean for Research at Tulane School of Medicine. He directs the Infectious Disease Aerobiology Core at the Tulane National Primate Research Center. His research focuses on aerosol transmission of pathogens, vaccine development, and nonhuman primate models for biothreat agents like Mycobacterium tuberculosis and SARS-CoV-2. Dr. Roy’s work emphasizes understanding respiratory infection mechanisms and evaluating medical countermeasures in high-containment environments. Education: MSPH in Environmental Health Sciences (Tulane University), PhD in Preventive Medicine (University of Iowa). Research Interests: Aerobiology of airborne diseases, aerosol infection models, immunogenicity of vaccines, and pathogen transmission dynamics. His lab develops models for biothreat agents such as Burkholderia pseudomallei and evaluates therapeutics for toxins like SEB and ricin. Recent studies include pediatric tuberculosis outcomes and SARS-CoV-2 transmission in nonhuman primates. Scientific Contributions: Over 150 peer-reviewed articles on aerobiology, vaccine efficacy, and emerging pathogens. Editorial roles include Associate Editor for Frontiers in Cellular and Infection Microbiology and board member of the Journal of Medical Primatology . Labs/Teams: Leads high-containment (BSL-3) facilities for pathogen studies. Collaborates with extramural labs on biothreat agent research and medical product evaluation.

• Microbiology
• Immunology
• Bacterial Pathogenesis
• +۷ مورد دیگر

Paul Brett is a Professor in the Department of Microbiology and Immunology at the University of Nevada, Reno School of Medicine. With over 25 years of experience researching Burkholderia pseudomallei , the causative agent of melioidosis, Dr. Brett leads a laboratory focused on understanding molecular mechanisms of bacterial pathogenesis and developing effective vaccines against this significant infectious disease. Dr. Brett received his B.Sc. in Biochemistry from the University of Victoria and his Ph.D. in Bacterial Pathogenesis from the University of Calgary. His academic credentials have supported a distinguished career investigating bacterial virulence mechanisms, particularly focusing on how B. pseudomallei evades host immune defenses through specialized surface structures. Dr. Brett's research program centers on elucidating how lipopolysaccharides and capsular polysaccharides expressed by B. pseudomallei contribute to immune evasion. His laboratory has developed significant expertise in carbohydrate purification/characterization, glycoconjugate synthesis, and comprehensive analysis of humoral/cellular immune responses. The ultimate goal of his research is to identify correlates of antigen-induced immunity against B. pseudomallei to develop safe, affordable, and effective melioidosis vaccines that could address this serious public health threat. Analysis of Dr. Brett's publication history reveals a consistent research trajectory with publications spanning from the early 2000s through 2025. His work demonstrates increasing sophistication in vaccine development approaches, with recent publications focusing on glycoconjugate vaccines, structural analysis of bacterial components, and innovative diagnostic methods for melioidosis. His research bridges molecular microbiology and translational immunology, with direct applications to vaccine design and development. Dr. Brett has participated in significant collaborative efforts, including the Melioidosis Diagnostic Workshop in 2013 and the Steering Group on Melioidosis Vaccine Development. These collaborations highlight his standing as a recognized expert in the field and his commitment to advancing international efforts to combat melioidosis. Though specific details about current students and grants are not provided in the available materials, Dr. Brett's active publication record through 2025 and his laboratory's described capabilities suggest he maintains a vibrant research program with ongoing funding and mentorship of graduate students and postdoctoral researchers. His work has direct relevance to both public health initiatives in melioidosis-endemic regions and biodefense preparedness efforts given B. pseudomallei 's classification as a Tier 1 select agent.

Stephan Reuterمشاهده پروفایل

استاد

• Plasma Physics
• Plasma Medicine
• Ultrafast Laser Spectroscopy
• +۴ مورد دیگر

Stephan Reuter is a Full Professor in the Department of Engineering Physics at Polytechnique Montréal , holding the TransMedTech Research Chair in Plasma Medicine . His work bridges plasma physics, biomedicine, and environmental technology through advanced diagnostics and interdisciplinary applications. Education: Dipl. Phys.-Ing. (Master in Engineering Physics), Dipl. Phys. (M.Sc. in Physics), Dr. rer. nat. (PhD) Affiliations: TransMedTech Institute, Institute of Biomedical Engineering, Alexander von Humboldt Foundation Alumnus Research Interests: Non-thermal plasma physics, plasma medicine, ultrafast laser diagnostics, plasma-liquid interactions, environmental remediation His 15 most recent publications (2022-2025) focus on cold atmospheric plasma jets for cancer therapy, agricultural sustainability, and microfluidic integration. These works span Plasma Medicine , Environmental Technology , and Advanced Diagnostics , with specific subfields like 3D tumor modeling, reactive oxygen species analysis, and precision plasma dosimetry. Scientific Leadership : Feodor Lynen Research Fellow (Princeton University, 2017-2018) Co-founder of Leibniz Institute's Plasma Medicine Group Editorial contributor to Plasma Sources Science and Technology Research Impact : Over 98 peer-reviewed journal articles Keynote speaker at ISPC26 (2025) Major grants: $3.4M for greenhouse plasma technology (2024), $1M NFRF Exploration Grant (2021) Labs & Collaborations : Polytechnique Montréal Plasma Biophysics Lab TransMedTech Institute International collaborations: Leibniz Institute (Germany), Queens University (UK), Lublin University (Poland)

• Pandemic Diseases
• Microbiology
• Biodefense
• +۳ مورد دیگر

Dr. Alison St. John serves as a Lecturer in the Advanced Academic Programs at Johns Hopkins University's Homewood Campus while working as a Scientist for the federal government, specializing in pandemic diseases, microbiology, biodefense, and medical intelligence. Her educational background includes: B.S. in Microbiology from The Pennsylvania State University M.S. in Genetics from Penn State (Walden program) M.Agr. in Animal Science from Penn State (Walden program) M.S. in Public Health from Penn State (Walden program) Ph.D. in Public Health Epidemiology from Penn State (Walden program) Dr. St. John's research integrates pandemic disease mitigation with regulatory science, developing early-warning diagnostics through Good Laboratory/Manufacturing Practices (GLP/GMP) and ISO 17025/9001 standards. Her work at federal laboratories focuses on biodefense pathogens with critical collaborations between the FDA and USDA for public health protection. As principal investigator for biodefense pathogen research, she secured grants for diagnostic development and served as ISO 17025 internal auditor, advancing regulatory frameworks for pandemic response. She operates within federal government laboratories while maintaining academic ties through JHU, driving cross-agency initiatives in medical intelligence and biodefense standardization.

• Attention Deficit and Disruptive Behavior Disorders
• Behavioral Disciplines and Activities
• Buddhism
• +۶ مورد دیگر

David Saunders, MD, PhD, is a Clinical Assistant Professor at the Yale Child Study Center within the Yale School of Medicine. He holds dual training in medicine and Buddhist studies, with a PhD from Emory University and an MD from Weill Cornell Medical College. His research focuses on mindfulness-based interventions for childhood ADHD and integrates Buddhist philosophy with neuroscience. He leads a clinical trial for a novel ADHD intervention under mentorship of Hedy Kober. Education includes a BA in theology from Boston College and Fulbright research in Nepal on Tibetan cultural perceptions of tuberculosis. Research interests span attention disorders, child behavior, neurosciences, and the philosophical underpinnings of mindfulness. His work bridges clinical practice with contemplative traditions, particularly examining how Buddhist meditation theories inform modern therapeutic approaches. Publications span vaccine trials, vector-borne diseases, and interdisciplinary studies on mindfulness. Current projects include a phase 2 clinical trial on chikungunya vaccines and studies on tick-borne pathogens. He collaborates with the Clinical and Affective Neuroscience lab at Yale. No specific awards are highlighted, though his work reflects innovative intersections between medicine, philosophy, and public health.

Paige Adamsمشاهده پروفایل

دانشیار

• Arbovirology
• Immunology
• Vaccine Development
• +۵ مورد دیگر

Paige Adams, D.V.M., Ph.D., is a Teaching Associate Professor at Kansas State University's Olathe campus since August 2013. Previously, she served as Assistant Professor and Postdoctoral Research Fellow in the Department of Pathology at University of Texas Medical Branch for nine years. Ph.D. in Immunology, Cornell University (2004) D.V.M. in Veterinary Medicine, Texas A&M University (1993) B.S. in Veterinary Science, Texas A&M University (1990) Adams focuses on One Health approaches in veterinary and human health domains. Her research explores innate and adaptive immune responses to arboviruses , particularly alphaviruses and flaviviruses, along with vaccine development for zoonotic diseases and biodefense applications. She contributes to graduate programs in Applied Biosciences , Veterinary Biomedical Science , and professional development initiatives in animal health regulatory affairs. Her scholarly work spans viral pathogenesis, vaccine chimera design, and immunological modeling, with key collaborations across institutions like University of Texas Medical Branch and Cornell University. Adams also integrates industry expertise through advisory boards and panels, emphasizing career pathways in animal health regulatory compliance and translational research .

Atin Adhikariمشاهده پروفایل

استاد

• Environmental Health Sciences
• Air Quality
• Bioaerosol Exposure Assessment
• +۷ مورد دیگر

Atin Adhikari is a Full Professor in the Department of Biostatistics, Epidemiology & Environmental Health Sciences at Georgia Southern University's Jiann-Ping Hsu College of Public Health. His career spans over two decades with prior roles as Associate Professor (2019–2024) and Assistant Professor (2014–2019) at the same institution, following a postdoctoral fellowship at the University of Cincinnati's Department of Environmental Health (2000–2005). Research Interests focus on environmental health sciences, particularly air quality, bioaerosol exposure assessment, and respiratory health. His work examines traffic-related air pollutants' impact on children's respiratory microbiomes, occupational hazards in construction and agricultural settings, and sustainable solutions for indoor air quality improvement in historical buildings. Scientific Contributions include leading CDC-NIOSH-funded studies on farm worker respiratory diseases, HUD/NIH-NIEHS grants on pesticide exposure, and current Partnership for Inclusive Innovation projects for air quality interventions. His research spans microbial ecology, climate change health impacts, and innovative detection methods for pathogens. Honors and Grants include multiple NIOSH, NIH, and NIEHS grants as Principal Investigator. He has served on national/international grant review panels for CDC, NIH, NSF, and foreign research councils.

Christopher C. Broderمشاهده پروفایل

استاد

• Virology
• Emerging Viruses
• Virus-Host Cell Interactions
• +۵ مورد دیگر

Christopher C. Broder is Professor and Chair of the Department of Microbiology and Immunology at Uniformed Services University of the Health Sciences (USU) School of Medicine. A faculty member since 1996, he was promoted to Full Professor in 2005 and has led transformative research in virology, particularly in emerging zoonotic viruses and countermeasure development. His work bridges basic science and clinical translation, with significant contributions to national biodefense efforts. Dr. Broder's educational background includes: B.S. in Biological Sciences (with honors), Florida Institute of Technology (1983) M.S. in Molecular Biology, Florida Institute of Technology (1985) Ph.D. in Microbiology and Immunology, University of Florida College of Medicine (1989) His research focuses on virus-host interactions for high-consequence pathogens including Nipah, Hendra, Ebola, and HIV-1. Key areas include viral entry mechanisms, receptor discovery, and development of vaccines/therapeutics. Notable achievements include identifying HIV-1 coreceptors (CXCR4/CCR5; Science 1996 Breakthrough of the Year), discovering ephrin-B2 as the henipavirus receptor, and creating the first commercialized BSL-4 vaccine (Equivac® HeV). His work exemplifies the One Health approach to zoonotic disease control. Analysis of his 15 most recent publications (2008-2024) reveals consistent leadership in structural virology, therapeutic antibody development, and translational countermeasures for henipaviruses. His team has pioneered structural characterization of viral glycoproteins, enabling rational vaccine design and cross-reactive antibody therapies now in clinical use. Recent work emphasizes broad-spectrum countermeasures against divergent viral variants. Dr. Broder's major honors include: Federal Laboratory Consortium Awards (2013, 2019, 2020) CSIRO Chairman’s Medal (2013) Carol Johns Medal (highest USU faculty honor) MHSRS Outstanding Research Awards (2020 Individual, 2021 Team) James J. Leonard Award for Translational Research (2016) He has mentored 13 graduate students and 15 postdoctoral fellows while securing major funding from NIH, DoD, and CEPI. His translational pipeline includes the HeV-sG vaccine (approved for horses in Australia), the m102.4 monoclonal antibody (used in 19 human emergency treatments), and multiple candidates in Phase 1 clinical trials. His research directly addresses military-relevant biological threats through the DoD's emerging infectious disease programs. As Department Chair and former Director of USU's Emerging Infectious Diseases PhD Program (2006-2018), Dr. Broder leads a multidisciplinary team collaborating with CSIRO (Australia), NIAID, and biotech partners. His laboratory maintains BSL-3/4 capabilities for high-containment pathogen research and serves as a critical node in global outbreak response networks for henipaviruses and other priority pathogens.

Steven W. Gravesمشاهده پروفایل

استاد

• Biomolecular Assemblies
• Protease Mechanisms
• Point of Care Medical Devices
• +۶ مورد دیگر

Steven W. Graves is a Professor in the Department of Chemical and Biological Engineering at the University of New Mexico, with a secondary appointment in the Department of Biochemistry and Molecular Biology. He serves as the Director of the Center for Biomedical Engineering and has held various leadership roles including Associate Dean for Research for the UNM School of Engineering and Director of the Biomedical Engineering Graduate Program. Dr. Graves received his Ph.D. from The Pennsylvania State University in 1998 and completed postdoctoral research at Los Alamos National Laboratory before joining UNM in 2008. His research spans two primary areas: Biomedical/Environmental Instrumentation and Diagnostics, and Biomolecular Engineering for Protease Studies, Screening, and Molecular Computation. His laboratory develops innovative technologies including low-cost portable flow cytometry systems for resource-limited settings, acoustic focusing methods for high-throughput cellular analysis, and molecular computation approaches for disease detection. Current research projects include enhanced imaging flow cytometry for plankton studies, parallel systems for high-throughput flow cytometry, and computing with biomolecules. Dr. Graves has received significant research funding from NIH, NSF, and USDA, and has been awarded the 2007 R&D100 award for the development of Portable Acoustic Cytometry. He has co-founded two companies, Eta Diagnostics, Inc. and Helion Scientific, Inc., to commercialize his research innovations. 2015-Present: Professor, Department of Chemical & Biological Engineering, University of New Mexico 2014: Associate Dean for Research, School of Engineering, University of New Mexico 2010-2014: Director, Biomedical Engineering Graduate Program, University of New Mexico 2008-2015: Associate Professor, Department of Chemical & Nuclear Engineering, University of New Mexico 2007-2008: Team Leader, Optical Spectroscopy and Instrumentation, Los Alamos National Laboratory His research group includes postdoctoral researchers, graduate students from multiple disciplines, and undergraduate students working collaboratively on interdisciplinary projects spanning engineering, biology, and chemistry.